Signos Alternatives: The Best CGM Weight-Loss Platforms for Every Use Case

What Signos Actually Offers (and Where It Falls Short)

Signos sells a subscription that bundles a CGM sensor (typically the Dexcom Stelo or Abbott Libre) with a proprietary app. The app tracks real-time glucose responses to meals, exercise, and sleep, then delivers nudges intended to keep glucose within a "weight-loss zone." A 2023 retrospective analysis published in Diabetes Technology & Therapeutics found that non-diabetic adults using CGMs for dietary feedback reduced their time in hyperglycemic ranges by roughly 30 minutes per day [1]. That is a real signal, but it is not the same as proven long-term weight loss.

The glucose-weight-loss link

The core premise is that blunting postprandial glucose spikes reduces insulin surges, which in turn reduces fat storage. This idea draws on legitimate physiology. A 2015 Cell study (N=800) demonstrated highly individualized glycemic responses to identical foods, supporting personalized nutrition [2]. The gap: no randomized controlled trial has shown that CGM-guided eating produces clinically meaningful weight loss (>5% body weight) in people without diabetes over 12 months or longer.

Cost and commitment

Signos charges $199 per month on an annual plan, or up to $399 month-to-month. Over a year, that is $2,388 to $4,788. Insurance does not cover CGMs for weight loss in non-diabetic individuals. The American Diabetes Association's 2024 Standards of Care recommend CGM for patients with type 1 or type 2 diabetes on insulin, not for general weight management [3].

No medication pathway

Signos does not prescribe weight-loss medications. For someone with a BMI ≥30 (or ≥27 with a weight-related comorbidity), the Endocrine Society's 2024 clinical practice guideline recommends considering pharmacotherapy when lifestyle interventions alone have not achieved target weight loss [4]. A CGM-only platform cannot address that recommendation.

Head-to-Head: Signos vs. Each Major Alternative

The CGM wellness market has four primary players and a growing set of prescription telehealth competitors. Here is how each compares.

Nutrisense: best for dietitian-guided metabolic coaching

Nutrisense pairs a CGM with access to a registered dietitian (RD). Plans range from roughly $175 to $350 per month. The RD reviews your glucose data, builds meal plans, and adjusts recommendations over time.

Where Nutrisense wins: human expert guidance. A 2022 systematic review in The BMJ found that dietitian-led interventions produced 1.5 to 3.2 kg greater weight loss than self-directed dieting over 12 months [5]. If your primary barrier is not knowing how to interpret glucose data, a real dietitian closes that gap faster than an algorithm.

Where Nutrisense loses: it still does not prescribe medications, and the monthly cost can exceed Signos on comparable plan tiers.

Levels: best for data-driven self-optimizers

Levels positions itself as a metabolic health research tool. Its "Metabolic Score" grades each meal on a 1 to 10 scale based on glucose response, and the app emphasizes long-form educational content. Levels costs approximately $199 per month (annual) with a CGM included.

Where Levels wins: depth of data visualization and educational content. Levels publishes peer-reviewed research partnerships and offers the most granular breakdown of glucose metrics among consumer CGM apps.

Where Levels loses: no dietitian access, no medication pathway, and a similar price point to Signos. For someone who wants to be told what to eat rather than analyze charts, Levels may overwhelm.

Veri: best budget CGM option

Veri, a Finnish-founded platform now operating in the U.S., starts around $150 per month. It provides glucose tracking, meal logging, and basic coaching through the app. Sensor options include the Abbott Libre 2 or Libre 3.

Where Veri wins: lowest price point. For someone who simply wants to see how foods affect their glucose and does not need a dietitian or extensive analytics, Veri is the most accessible entry.

Where Veri loses: the app's coaching algorithms are less developed than Signos or Levels, and there is no human coaching tier. The evidence base is the same limitation shared by all CGM-for-weight-loss apps.

GLP-1 telehealth platforms: best for clinically significant weight loss

This is the category that operates on a different evidence tier entirely.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss versus 2.4% with placebo at 68 weeks in the STEP-1 trial (N=1,961) [6]. Tirzepatide 15 mg (Zepbound) produced 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) [7]. These are the largest effect sizes ever recorded in obesity pharmacotherapy trials.

Telehealth platforms like HealthRX, Ro, and Found connect patients with licensed clinicians who can prescribe GLP-1 receptor agonists, sometimes in combination with metabolic monitoring. Monthly costs range from $199 to $500+ depending on medication tier and insurance coverage.

Where GLP-1 platforms win: proven, dose-dependent weight loss backed by phase III RCTs and FDA approval for chronic weight management. The 2024 Endocrine Society guideline specifically recommends semaglutide or tirzepatide as first-line pharmacotherapy for obesity [4].

Where GLP-1 platforms lose: side effects are common. In STEP-1, 44.2% of semaglutide-treated participants reported gastrointestinal adverse events (nausea, diarrhea, vomiting) [6]. These medications also require ongoing use; the STEP-1 extension trial showed that participants regained two-thirds of lost weight within one year of stopping semaglutide [8]. Cost without insurance can exceed $1,000 per month for branded formulations.

Choosing by Use Case: A Decision Matrix

Not every person with weight-loss goals needs the same tool. The right alternative to Signos depends on your metabolic status, budget, and what has (or has not) already worked.

Use case 1: curiosity about glucose responses, no obesity diagnosis

If your BMI is under 27, you have no metabolic comorbidities, and you want to learn which foods spike your glucose, a short CGM experiment (1 to 3 months) on Veri or Levels will answer that question at the lowest cost. Long-term CGM use in this population has no evidence of sustained benefit.

Use case 2: prediabetes or insulin resistance

The CDC's Diabetes Prevention Program (DPP) demonstrated that lifestyle intervention reduced type 2 diabetes incidence by 58% over 2.8 years in adults with prediabetes [9]. A CGM adds biofeedback to that lifestyle work. Nutrisense is the strongest option here because the dietitian can align CGM data with DPP-style dietary targets. A 2021 study in The Lancet Digital Health found that CGM-guided dietary counseling reduced HbA1c by 0.3% more than standard counseling alone in prediabetic adults over 6 months [10].

Use case 3: BMI ≥30 or BMI ≥27 with comorbidities

This is where pharmacotherapy enters the conversation. The Endocrine Society recommends medication for patients who have not achieved target weight loss through lifestyle alone [4]. A CGM can complement a GLP-1 prescription by revealing how medication changes glucose dynamics, but the CGM alone is not a substitute for the medication. Dr. Caroline Apovian, co-director of the Center for Weight Management at Brigham and Women's Hospital, has stated: "Obesity is a chronic disease that requires chronic treatment. Behavioral tools are necessary but often insufficient on their own" [11].

Use case 4: post-bariatric surgery glucose monitoring

After Roux-en-Y gastric bypass, up to 30% of patients experience reactive hypoglycemia [12]. A CGM is medically useful in this population, and insurance may cover it. Nutrisense or a direct CGM prescription from your surgeon's office is more appropriate than Signos, which markets to a general weight-loss audience.

The Evidence Gap: What CGM Weight-Loss Apps Have Not Proven

A recurring theme across all consumer CGM platforms (Signos included) is the absence of large, randomized, controlled trials demonstrating that CGM use causes clinically significant weight loss in non-diabetic adults.

What exists

Observational and retrospective data suggest CGM users make short-term dietary changes. A 2024 review in Obesity Reviews analyzed 11 studies on CGM in non-diabetic populations and concluded that real-time glucose feedback improves short-term dietary choices but that "evidence for sustained weight loss or metabolic improvement beyond 6 months is lacking" [13].

What does not exist

No CGM wellness company has published a phase III randomized trial with a primary endpoint of percent body weight change at 12 months. By contrast, GLP-1 receptor agonists have multiple key trials (STEP, SURMOUNT, SCALE) with thousands of participants and follow-up periods of 68 to 72 weeks [6][7][14].

The regulatory distinction

The FDA clears CGM hardware as a medical device. The apps built on top of that hardware (Signos, Levels, Nutrisense, Veri) are wellness products, not FDA-approved treatments. This distinction matters for anyone expecting a medical-grade intervention.

Cost Comparison Table

Below is an approximate monthly cost breakdown (2026 pricing, subject to change):

| Platform | Monthly cost (annual plan) | CGM included | Dietitian access | Medication prescribing | |---|---|---|---|---| | Signos | $199, $259 | Yes | No | No | | Nutrisense | $175, $350 | Yes | Yes (RD) | No | | Levels | $199 | Yes | No | No | | Veri | $150 | Yes | No | No | | HealthRX (GLP-1) | $199, $500+ | No | Clinician consult | Yes | | Ro Body | $145, $499 | No | Clinician consult | Yes | | Found | $129, $499 | No | Clinician consult | Yes |

Insurance coverage for GLP-1 medications varies widely. A 2024 KFF analysis found that 40% of large employer plans covered at least one GLP-1 for obesity, up from 25% in 2023 [15].

When a CGM Makes Sense Alongside Medication

The either/or framing of "CGM vs. GLP-1" is a false binary. For patients on semaglutide or tirzepatide, a CGM can show the real-time metabolic impact of the medication, particularly reduced postprandial spikes and improved fasting glucose stability. A 2023 post hoc analysis of SURMOUNT-1 data published in Diabetes Care showed that tirzepatide normalized glucose tolerance in 95.3% of participants with prediabetes at baseline [16]. A CGM lets patients see that normalization happen in real time.

Practical pairing

The most evidence-aligned approach for a patient with obesity and prediabetes: start GLP-1 pharmacotherapy under clinician supervision, add a 1 to 3 month CGM window to build dietary pattern awareness, then discontinue the CGM once behavioral habits are established. This avoids the indefinite $200+ monthly CGM subscription while capturing the educational benefit.

Who should skip the CGM entirely

If you are metabolically healthy (normal fasting glucose, normal HbA1c, BMI <25) and simply want to lose 5 to 10 pounds, a CGM is an expensive way to learn something a food diary and bathroom scale can teach you. The American College of Physicians' 2024 guidance on obesity management does not mention CGMs as a recommended intervention for general weight loss [17].

Red Flags in CGM Weight-Loss Marketing

Watch for these patterns across all platforms, not just Signos:

• "Metabolic optimization" without defining the endpoint. If a company does not specify which biomarker it aims to improve by how much, the claim is unfalsifiable.
• Testimonials as evidence. Before-and-after stories are not controlled data. A 2021 analysis in Annals of Internal Medicine found that weight-loss testimonials overstate average outcomes by 300% or more [18].
• "Personalized nutrition" implying clinical treatment. Personalized nutrition is a valid research field. It is not the same as personalized medicine for a diagnosed condition.

The Federal Trade Commission's Health Products Compliance Guidance requires that health benefit claims be supported by "competent and reliable scientific evidence," typically meaning at least one well-designed RCT [19]. No consumer CGM app has met that threshold for a weight-loss claim.

The Bottom Line: Match the Tool to the Problem

A CGM is a sensor. It measures interstitial glucose. What you do with that data depends on the app, the coaching, and the clinical context. Signos is one way to interpret that data, but it is not the only way, and for many people it is not the best way. If your goal is metabolic curiosity, Veri or Levels costs less. If you need dietary guidance, Nutrisense adds a real dietitian. If you need clinically significant weight loss, a GLP-1 prescription has 10x the evidence base. The Endocrine Society, the AMA, and the WHO all classify obesity as a chronic disease requiring chronic treatment [4]. Treat the tool selection with the same seriousness you would give any other medical decision.